N-acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency.

N-acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency - a randomized double-blind placebo-controlled multicenter study in patients not on renal replacement therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20378

Enrollment

246

Registered

2005-08-27

Start date

2006-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal insufficiency (not yet requiring renal replacement therapy)

Interventions

Patients are randomly assigned to receive either N-acetylcysteine before and after administration of the contrast agent (acetylcysteine group) or placebo at the same time points (control group). N-ac

Eligibility

Inclusion criteria

Inclusion criteria: 1. (Chronic or acute) renal insufficiency (not presently on renal replacement therapy) defined as a plasma creatinine > 180 ìmol/L; 2. Planned diagnostic imaging procedure requiring the use of intravenous radiographic contrast agents; 3. Admitted to one of the participating intensive care units.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. No informed consent.

Design outcomes

Primary

Measure	Time frame
1. Rise in plasma creatinine > 25% within 48 hours after contrast administration. Need for CVVH therapy at any moment during stay in ICU; 2. Duration of CVVH therapy, if initiated; 3. Renal insufficiency (for which ongoing renal replacement therapy) at ICU-discharge .	—

Contacts

Public ContactM.J. Schultz

Meibergdreef 9

m.j.schultz@amc.uva.nl+31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)